{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:32:55Z","timestamp":1792359175677,"version":"4.4.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"5","funder":[{"DOI":"10.13039\/100000030","name":"centers of disease control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The 2021 update of the Centers for Disease Control and Prevention clinical guidelines for human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) recommended both antigen-antibody (Ag\/Ab) and RNA testing at PrEP initiation and routine follow-up. We assessed the real-world use and performance of HIV tests among oral PrEP users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An oral PrEP user cohort was constructed using the HealthVerity database that included linked diagnoses, laboratory tests, and prescriptions from December 2018 to August 2023. Data were stratified by pre\u2013guideline update (2019\u22122021) and post\u2013guideline update (2022\u22122023) periods. For each period, we assessed the agreement between same-day HIV Ag\/Ab and RNA results and calculated the false-positive rates and positive predictive values of HIV Ag\/Ab and RNA tests compared with the adjudicated HIV status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The HIV RNA testing rate for follow-up, per 100 person-years, increased from 16 before to 123 after the guideline update. The positivity rate of HIV RNA tests decreased from 1.39% to 0.22%. Overall agreement between Ag\/Ab and RNA results remained high. The false-positive rates of HIV Ag\/Ab and RNA testing remained similar, but the positive predictive value of HIV RNA testing for PrEP follow-up decreased from 100% to 67%. We estimated that 8226\u20139900 RNA tests would be needed for 1 HIV diagnosis earlier than would be detected with Ag\/Ab testing alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>HIV RNA testing did not provide additional value to Ag\/Ab testing during routine follow-up of oral PrEP users. Considering the cost and logistical complexity of HIV RNA testing, its use as a routine test during follow-up of oral PrEP users warrants reconsideration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf230","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T08:03:59Z","timestamp":1746259439000},"page":"e330-e337","source":"Crossref","is-referenced-by-count":3,"title":["Limited Utility of HIV RNA Testing to Monitor Oral Preexposure Prophylaxis Use: A Real-World Cohort Study\u2014United States, 2019\u20132023"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9042-6202","authenticated-orcid":false,"given":"Weiming","family":"Zhu","sequence":"first","affiliation":[{"name":"HIV Research Branch, Division of HIV Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7562-7647","authenticated-orcid":false,"given":"Kevin P","family":"Delaney","sequence":"additional","affiliation":[{"name":"HIV Research Branch, Division of HIV Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3137-8594","authenticated-orcid":false,"given":"Ya-lin A","family":"Huang","sequence":"additional","affiliation":[{"name":"HIV Research Branch, Division of HIV Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0329-7036","authenticated-orcid":false,"given":"Rupa R","family":"Patel","sequence":"additional","affiliation":[{"name":"HIV Research Branch, Division of HIV Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1585-1310","authenticated-orcid":false,"given":"Athena P","family":"Kourtis","sequence":"additional","affiliation":[{"name":"HIV Research Branch, Division of HIV Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4942-7905","authenticated-orcid":false,"given":"Karen W","family":"Hoover","sequence":"additional","affiliation":[{"name":"HIV Research Branch, Division of HIV Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"2025122403225384900_ciaf230-B1","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"2025122403225384900_ciaf230-B2","author":"Centers for Disease Control and Prevention, US Public Health Service"},{"key":"2025122403225384900_ciaf230-B3","author":"World Health Organization"},{"key":"2025122403225384900_ciaf230-B4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.15585\/mmwr.mm6741a3","article-title":"HIV preexposure prophylaxis, by race and ethnicity\u2014United States, 2014-2016.","volume":"67","author":"Huang","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025122403225384900_ciaf230-B5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/QAI.0000000000001374","article-title":"Characterization of HIV seroconverters in a TDF\/FTC PrEP study: HPTN 067\/ADAPT.","volume":"75","author":"Sivay","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025122403225384900_ciaf230-B6","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1097\/QAD.0000000000001577","article-title":"The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion.","volume":"31","author":"Donnell","year":"2017","journal-title":"AIDS"},{"key":"2025122403225384900_ciaf230-B7","author":"Branson"},{"key":"2025122403225384900_ciaf230-B8","doi-asserted-by":"crossref","first-page":"105058","DOI":"10.1016\/j.jcv.2021.105058","article-title":"Impact of the 2014 CDC HIV testing guidelines on detection of acute HIV infections.","volume":"146","author":"Crowe","year":"2022","journal-title":"J Clin Virol"},{"key":"2025122403225384900_ciaf230-B9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jcv.2014.10.010","article-title":"An HIV-1 RNA test following a reactive fourth-generation antigen\/antibody combination assay confirms a high proportion of HIV infections","volume":"61","author":"Westheimer","year":"2014","journal-title":"J Clin Virol"},{"key":"2025122403225384900_ciaf230-B10","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1016\/S2352-3018(24)00130-9","article-title":"HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomized, controlled, phase 3 trial","volume":"11","author":"Wohl","year":"2024","journal-title":"Lancet HIV"},{"key":"2025122403225384900_ciaf230-B11","author":"HealthVerity"},{"key":"2025122403225384900_ciaf230-B12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0895-4356(98)00048-1","article-title":"Approximate standard errors and confidence intervals for indices of positive and negative agreement","volume":"51","author":"Graham","year":"1998","journal-title":"J Clin Epidemiol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf230\/63055978\/ciaf230.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/5\/e330\/63055978\/ciaf230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/5\/e330\/63055978\/ciaf230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:22:59Z","timestamp":1766564579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/5\/e330\/8125152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":12,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,5]]},"published-print":{"date-parts":[[2025,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf230","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,15]]},"published":{"date-parts":[[2025,5,5]]}}}